Advertisement mid banner S-Tech 1
Advertisement: HCR Hewitsons mid banner
Advertisement: Cambridge Network mid banner
Advertisement: partnersand mid banner
Advertisement: SATAVIA mid banner
Advertisement: Simpsons Creative mid banner
Advertisement: Birketts mid banner
Advertisement: Bar Ellison mid banner property
Mid banner advertisement: BDO
Advertisement: CJBS mid banner
Advertisement: Mogrify mid banner
Barr Ellison Solicitors – commercial property
Advertisement: EBCam mid banner
ARM Innovation Hub
Advertisement: Excalibur Healthcare mid banner
Cambridgeand mid banner advertisement
Advertisement: Kao Data Centre mid banner
Advertisement: RSM mid banner
10 June, 2022 - 01:00 By Tony Quested

SMC launches Cambridge Pharma with 20,000 sq ft facility

SMC Ltd., a leading solutions provider in the manufacturing of pharmaceutical and medical devices, has opened Cambridge Pharma – a new business offering pharmaceutical development services, including sterile fill-finish. 

The new 20,000 sq ft facility, located at the Cambridge Research Park, includes a purpose-built sterile fill-finish facility, a process development laboratory and an analytical laboratory. 

Services include process development and scale up, sterile fill finish for clinical trials, QC and stability testing and QP release of clinical trials supplies.

Chetan N. Patel, Owner and CEO of SMC Group, has a strategic vision for the company: “We value pharmaceutical partnerships and continue to expand services in development, manufacturing and analytical testing to help accelerate drug product development. 

“We are proud to launch ‘Cambridge Pharma’ as a part of our continued focus, growth and commitment to pharmaceutical products and services.”  

The sterile fill finish facility is designed to meet up-to-date regulatory requirements and includes a state-of-the-art dynamic and independent HVAC systems and two clean rooms. Each clean room is equipped with isolators and fill finish equipment to support batch sizes from 100 units to 15,000 units in vials, cartridges, or syringes. 

Cambridge Pharma’s industrialisation engineers can take a customer’s laboratory scale formulation and develop a process for clinical trials in phases one to three including process development and filling of viscous formulations, suspensions and gels. 

Nonstandard primary drug containers can be accommodated, and container closure integrity tests and associated equipment can also be developed. The company says its QC and QA teams can undertake stability and QC testing and the QPs can release clinical trial supplies. Cambridge Pharma project managers ensure program schedules are respected to meet pharma companies target trial start dates.

Barbara Lead, Cambridge Pharma CEO, said: “I am really proud of our new facilities and the experience and expertise of our teams. We can provide a range of pharmaceutical development services and we have experience with difficult to fill formulations. 

“We aim to provide an excellent service to customers for clinical trial supplies which are always on the critical path to market.”

SMC Group comprises SMC Ltd, Oval Medical Technologies and Cambridge Pharma Ltd. With more than 34 years of medical manufacturing experience and facilities in California, Wisconsin, Massachusetts, Ohio, UK, India and Costa Rica, the SMC group provides contract manufacturing services to the medical device and diagnostics industries and end-to-end integrated services for clinical and commercial manufacturing of combination products for pharmaceutical customers.

Newsletter Subscription

Stay informed of the latest news and features